$3.2 million project targets MDM2 in triple-negative breast cancer
Apr 23, 2026
A $3.2 million research collaboration is developing a drug that directly breaks down MDM2 in triple-negative breast cancer. Early laboratory models showed tumour shrinkage, and the team is studying dosing, safety and performance.